ENSC Ensysce Biosciences Inc

$ENSC keep eyes on $ICU my biggest holding—- way undervalued! started to move. bullion dollar MC potential within 12 months if adult phase III approved mud 2027. same SCD device already pediatric FDA HDE approved- results undeniable dyor

$ENSC Ensysce is accelerating its global investor and strategic partnership outreach as we advance CY200, our lead program for Complex Regional Pain Syndrome (CRPS)—a debilitating condition with no effective treatment options today. Our President, James Morrison, recently engaged with leading family offices at the Family Office Summit in Dubai, introducing Ensysce’s differentiated severe chronic pain pipeline and initiating relationship-building with long-term, globally oriented investors and strategic partners. “Ensysce is entering a pivotal stage in its evolution. Expanding our network of sophisticated global investors and strategic partners is essential to advancing our mission,” said Morrison. This outreach follows September’s submission of our CY200 Phase 2 protocol to the UK MHRA, a key regulatory milestone. As we advance toward Phase 2, we are aligning with investors and partners who recognize the unmet need in CRPS and share our long-term vision for transforming pain management.

$ENSC Our focus for CY200 is on advancing its clinical and regulatory preparation for treatment of Complex Regional Pain Syndrome Type 1. The Cy Biopharma acquisition added its clinical-stage, FDA Orphan Drug-designated program to Ensysce’s pipeline and we immediately hit a number of milestones. In September, the Phase 2a protocol was submitted to the UK MHRA for review of a randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of CY200 in adults with CRPS Type 1. In September we unveiled the CY200 program to more than 320 pain management professionals at PAINWeek, following which Dr. Richard Langford contributed his clinical perspectives at an FDA hearing on therapeutic uses of psychedelic drugs.

$ENSC The CRPS treatment landscape is evolving, with various programs targeting different stages of the disease. While several emerging therapies focus on early‑stage intervention, CY200 is uniquely positioned for patients suffering from persistent, treatment‑resistant CRPS—individuals who continue to experience severe pain despite exhausting conventional options. This population faces a profound unmet need. Many progress through multiple classes of medications, infusion therapies, nerve blocks, and even invasive procedures, yet still fail to achieve sustained relief. CY200 is designed specifically for these patients, representing a differentiated opportunity in a segment where therapeutic innovation is urgently needed. Cantor Fitzgerald estimates approximately 40,000 potentially eligible U.S. patients for CY200 and models $1.5 billion in unadjusted global peak sales, reflecting the significant commercial potential of a therapy capable of addressing this refractory CRPS population.

$ENSC this is a first in its class breakthrough anti abuse tech. with fast track status. that doesn't mean a few months after phase 3 is enrolled. maybe a year or two instead of 3-5. but it wouldn't surprise me if after approval, all regulatory agencies in every country around the world end up requiring this or similar tech built into all opioid prescribed meds until the end of time... I mean. it only makes sense!!!

$ENSC wow 2 bucks for a drug that would possibly end painkiller addiction, save lives, and families, and money,...

$ENSC The only reason Bob Gower made his purchase is to outvote retail investors during the next vote on dilution. It’s as simple as that. Without dilution to raise capital, the company is effectively dead. It’s not for nothing that they are looking for new investors in the Middle East.

$ENSC The new companies involved in the deal will expect a return on investment!!! Lynn will not be allowed to bury this company going fwd IMO! big money is now part of ENSC, bigger pipeline and cash backing! Love to see SP jump over $1 this quarter. very possible imo!!! lets see

$ENSC for the first time in years I ’think’ algos are set to push SP higher! we need a safer better Opioid!!!! wish Lynn was replaced but this one looks strong! could well finally be ready to move to try value over $4 IMO dyor

$ENSC why you not release data if study completed August 31 you mentioned in previous post. Why holding data and pinning stock every day .50-.52. And posting so many good news

$ENSC Breakthrough Therapy Designation: The FDA granted this exclusive status to PF614-MPAR, which is only awarded to drugs showing preliminary evidence of radical improvement over existing treatments.

$ENSC That’s enough for me; I’m out and have further increased my Immx Biopharma position. Good luck to everyone here. 😎

$ENSC There’s always a slight pre-market rise to lure in new investors. Then comes the rude awakening—slipping a little lower every day. Management couldn't care less about its investors.

$ENSC Positive ENSC development: Series C holders agreed to remove their potential cash-redemption right, reducing a possible future cash liability for the company. Importantly, no new shares or additional dilution were introduced by this amendment. It also suggests Series C investors remain focused on eventual equity conversion rather than a cash exit — a small but meaningful cleanup of ENSC’s post-Cy capital structur

$ENSC Data won't be out until Jesus returns to Earth. Since they went public on June 30, 2021, their performance has gone from bad to worse. There have been three reverse splits: October 28, 2022 (1-for-20); March 31, 2023 (1-for-12); and December 3, 2024 (1-for-15). Definitly a worst management.

$ENSC you are Right. All this big funds will buy .40 stock then get. 1.50 RS. 20$ stock then it get dillute to 2$ Then they can claim loss in tax. Are you in high school

$ENSC It’s almost 2 months they complete overdose study. Why no data till now ? Holding and manipulating stock price. Why? Just to scare retail investors and get their shares.

$ENSC AI! No, that is not correct. Ensysce Biosciences does not have 400 million shares outstanding. The actual number of outstanding common shares is significantly lower, at approximately 19.46 million shares. However, there is a specific reason why the 400 million figure is circulating: Shareholders planning to sell: SEC filings from late October 2026 show that existing shareholders have registered plans to potentially sell up to 433.91 million shares in the future. What does this mean? This typically involves the registration of underlying shares that could be issued if investors choose to exercise their warrants, convertibles, or financial agreements. Therefore, these are not shares available on the market today, but rather a potential future dilution. In summary: The shares actually trading on the stock market today amount to just under 20 million. The rumor of 400 million stems from a registration document for potential future sales by financial partners.

$ENSC R/S is coming...they know it!...we know it!...been on this journey so many times with many tickers...they all use the same playbook...same language, and tactics....always the same result....avg down as close to the price if you havent already...it won't hurt as hard, when the announcement comes!

$ENSC OMG BOOM BOOM BOOM!!! And watch $TRUG BOOM IMMINENT THIS DAY IS GOING TO FUCKING ROCK WHOA